Urinary retention (frequency unknown): Since urinary retention may occur, patients should be monitored carefully. When symptoms are observed, administration should be discontinued, and appropriate measures should be taken.
Hepatic dysfunction (frequency unknown): Since hepatic dysfunction with increased AST(GOT), ALT(GPT) and bilirubin may occur, patients should be monitored carefully. When these abnormalities in laboratory test values are observed, administration should be discontinued, and appropriate measures should be taken immediately.
Paralytic Ileus (frequency unknown): When symptoms including severe constipation and abdominal distention are observed, administration should be discontinued, and appropriate measures should be taken.
Hallucination/delirium (frequency unknown): When these symptoms are observed, administration should be discontinued, and appropriate measures should be taken.
QT prolongation, ventricular tachycardia (frequency unknown): It has been reported that QT prolongation, ventricular tachycardia, atrioventricular block, bradycardia, etc. occur. When these symptoms are observed, administration should be discontinued, and appropriate measures should be taken.
Other adverse reactions: See Table 8.

View ADR Reporting Link